Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 4/20 | 0.35 |
| ▸ | PDE2A | O00408 | 6/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894181 | 0.85 | ALDH1A1 (0.43) | HDAC3HDAC1HDAC2HDAC6CYP3A4 | |
| SCHEMBL3897720 | 0.82 | OPRM1 (0.38) | HDAC3HDAC1HDAC2HDAC6AKT1 | |
| SCHEMBL3899787 | 0.80 | TACR1 (0.43) | HDAC3HDAC1HDAC2HDAC6SLC6A4 | |
| SCHEMBL3895028 | 0.80 | POLB (0.39) | AKT1CYP3A4 | |
| SCHEMBL3895035 | 0.80 | PDE2A (0.43) | PDE2ASLC6A2SLC6A4SLC6A3KCNH2 | |
| Formic Acid SCHEMBL3898641 | 0.78 | CYP2C19 (0.41) | HDAC3HDAC1HDAC2HDAC6AKT1 | |
| SCHEMBL5169982 | 0.77 | CYP2C19 (0.44) | HDAC3HDAC1HDAC2HDAC6AKT1 | |
| SCHEMBL5169120 | 0.74 | HDAC3 (0.38) | HDAC3HDAC1HDAC2HDAC6MCHR1 | |
| SCHEMBL31036999 | 0.72 | HDAC3 (0.46) | HDAC3HDAC1HDAC2HDAC6PDE2A | |
| SCHEMBL27931095 | 0.71 | SLC6A4 (0.33) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521449-B2 | 4-arylmorpholin-3-one derivatives, their preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-04-21 | — | — | US | disclosed |
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142349-A1 | 4-ARYLMORPHOLIN-3-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF | ADRB3, ADRA2C, OPRK1 | HDAC3 378/4885HDAC1 1155/4885HDAC2 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.